UniPharma Co., Ltd. (TPEX:6621)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.85
-0.20 (-1.53%)
Apr 29, 2026, 1:45 PM CST
-17.36%
Market Cap 465.06M
Revenue (ttm) 88.44M
Net Income (ttm) -40.54M
Shares Out 35.50M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,164
Average Volume 219,453
Open 13.05
Previous Close 13.05
Day's Range 12.50 - 13.55
52-Week Range 11.40 - 16.10
Beta -0.14
RSI 49.42
Earnings Date May 20, 2026

About UniPharma

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves m... [Read more]

Sector Healthcare
Founded 1998
Employees 31
Stock Exchange Taipei Exchange
Ticker Symbol 6621
Full Company Profile

Financial Performance

In 2025, UniPharma's revenue was 88.44 million, a decrease of -5.36% compared to the previous year's 93.46 million. Losses were -40.54 million, 63.4% more than in 2024.

Financial Statements

News

There is no news available yet.